Back to Agenda
ON DEMAND - New Drugs Regulatory Program Modernization
Session Chair(s)
Kevin Bugin, MS, RAC
Head of Global Regulatory Policy and Intelligence, Amgen, United States
The New Drugs Regulatory Program is undergoing a modernization. Leaders of the modernization will share their vision for the New Drugs Regulatory Program, the strategic objectives of modernization, and updates on key initiatives.
Learning Objective : Recognize the objectives and goals of the New Drugs Regulatory Program Modernization; Define the implications of the modernization process on new drug review and regulation activities.
Speaker(s)
Impetus for and Vision of the New Drugs Regulatory Program Modernization
Retired, Principal Deputy Commissioner, FDA , United States
Strategic Objectives of the New Drugs Regulatory Program Modernization
Consultant, Peter Stein Consulting, LLC, United States
Impact of the New Drugs Regulatory Program Modernization on the Office of New Drugs and Public Health
Chief Executive Officer, Accumulus Synergy, United States
Have an account?